About Us

PURAP is developed by PRS Medical Technologies, Inc. (“PRS”), a privately-held company engaged in the development, manufacture, and commercialization of medical devices to prevent and expedite treatment of pressure ulcers/sores, also known as decubitus ulcers. PRS’s technology applies laws of physics to minimize focalized peak skin interface pressures at or near bony prominences that are typically associated with formation and existence of pressure ulcers.  PRS strives to improve people’s lives through easy to use products based upon patent pending technologies that enable low cost alternatives to complicated and expensive products that are less effective than PRS products in lowering peak skin interface pressures. PURAP is a FDA registered product.

Our Story

PRS was founded in 2011 to develop technologies that minimize peak skin interface pressures of products that are in direct contact with people.  PRS believes that the lowest peak skin interface pressures will result in lowest rates of pressure ulcers.

Our Team

George Choi, Co-founder & CEO

George is the co-founder of PRS Medical and an experienced medical device executive.  Before PRS Medical he was a founder, President and CEO of Pavad Medical, a venture funded obstructive sleep apnea company and also a co-founder of Therative Inc, a venture funded aesthetics company. For ten years, George was a General Partner at MedVentures Associates and led investments in many successful healthcare companies.  He started his medical device career as a corporate lawyer with Wilson, Sonsini, Goodrich and Rosati where he served as an outside general counsel for approximately 100 corporate clients.

Nikhil Bhat, Co-founder & Technical Lead

Nikhil Bhat is the co-founder of PRS Medical and an experienced medical device technologist. He is a hands-on engineering leader with track record of innovation with 8 issued patents and more than 30 patents pending. Before founding PRS Medical, he worked at Acclarent, Inc., a Johnson & Johnson Ethicon company, developing technologies for treating pediatric otitis media. He started his medical device career at Pavad Medical, a venture funded sleep apnea company where he held several positions.

 

Board of Directors

William H.C. Chang

William is the Chief Executive Officer of Westlake Development Company, a real estate development company, and Chairman of Westlake International Group, a privately held diversified investment company whose investments span private and public equities, including venture capital, professional sports, media and entertainment, emerging technologies, life sciences, and real estate. William’s associations and affiliations include: the Asian Business League (Founding Chairman); California International Relations Foundation (Director); Chinese American Association of Commerce (Founder); City Club of San Francisco (Founding Governor); Harvard University (Asia Center and Committee on University Resources); and World President’s Organization. Mr. Chang is the Co-Owner and General Partner of D. C. United. He is on the Executive Committee of the San Francisco Giants Baseball Club and on the Board of Directors of U.S.A. Rugby. Mr. Chang has a bachelor’s degree in Economics from Harvard College, Cambridge, Massachusetts. Mr. Chang is involved in numerous early stage medical and technology companies, with a particular focus on clean/green, M2M, mobile, and cloud based applications, both as an investor and director.

Kevin McLeod

Kevin is an experienced medical device executive having launched more than 30 major product platforms in the United States, Europe and Asia during 17 years with Stryker Corporation where he also guided business development activity to achieve U.S. and global growth of 20% annually. Kevin currently serves as the Managing Director of the Michigan Medical Device Accelerator, a business and idea accelerator that focuses on early stage investments in medical device technologies. He is responsible for the commercialization, financial management, talent acquisition and operational administration at the Accelerator.

 

Scientific Advisors

Wally Buch, MD

Wally has been an angel investor in many successful startup companies, including Neoforma (NEOF). He received his MD from Hahnemann University in Philadelphia, Pennsylvania, and completed his internship and residency in General and Cardiovascular Surgery at Stanford University Hospital. He had a successful private practice in Cardiovascular and Thoracic Surgery at both Stanford University Hospital in Palo Alto and Sequoia Hospital in Redwood  City for more than 25 years. He is a Diplomat of the American Board of Surgery and the American Board of Thoracic Surgery. Currently Wally is a Venture Partner at MedVentures, and a Director of 3 early stage companies.

Mark Davies, MD

Mark is an Orthopaedic surgeon for Kaiser Permanente.  He attended Stanford University, where he played rugby and majored in Biology.  Prior to attending medical school, he worked at Oracle Corporation for two years.  After UCLA Medical School, he completed his orthopedic residency also at UCLA, including a dedicated research year.  He has published articles in a number of orthopedic journals as well as presented at national meetings.  Following his time at UCLA, Dr. Davies completed a yearlong fellowship with Dr. James Andrews of Birmingham, AL.  He is board certified by the American Board of Orthopaedic Surgery in addition to having a Certificate of Additional Qualification (CAQ) in Sports Medicine.

Luiz Da Silva, Ph.D

Luiz has a doctorate in physics and more than 10 years of research and development experience in the medical device industry. He is a fellow of the American Physical Society and the Optical Society of America.  He has over 200 publications and 52 issued patents, and his research has earned him awards from the American Physical Society, the Institute of Electrical and Electronics Engineers, R&D 100 and the U.S. Department of Energy.